Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levonorgestrel intrauterine ultra low-dose - Bayer HealthCare Pharmaceuticals

Drug Profile

Levonorgestrel intrauterine ultra low-dose - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY 86-5028; Blusiri; Fleree; G04209C; Jaydess; LCS (ULD LNG); LCS - Bayer; LCS G04209B; LCS12; LCS16; Levonorgestrel contraceptive intrauterine systems - Bayer; Levonorgestrel ultra low-dose IUD; Levonorgestrel ultra low-dose IUS; LNG-IUS; LNS ultra low-dose IUD; LNS ultra low-dose IUS; Skyla; Ultra low-dose levonorgestrel intrauterine - Bayer; Ultra low-dose LNG intrauterine - Bayer

Latest Information Update: 25 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 25 Jan 2019 Levonorgestrel intrauterine ultra low-dose is not yet available for Pregnancy (Prevention) in Iceland, Germany, Bulgaria, Italy, Luxembourg, Malta, Romania, Slovakia and Slovenia (Intrauterine)
  • 25 Jan 2019 Launched for Pregnancy (Prevention) in Estonia, prior January 2019 (Intrauterine)
  • 25 Jan 2019 Launched for Pregnancy (Prevention) in Latvia prior January 2019 (Intrauterine)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top